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Hypersensitivity reactions are the most frequent dose-limitingadverse reactions to Escherichia coli-derived asparaginase in pedi-atric acute lymphoblastic leukemia (ALL) patients. The aim of the
present study was to identify associations between sequence-based
Human Leukocyte Antigen Class II region alleles and asparaginase
hypersensitivity in a Hungarian ALL  population. Four-digit typing of
HLA-DRB1 and HLA-DQB1 loci was performed in 359 pediatric ALL
patients by using next-generation sequencing method. Based on geno-
typic data of the two loci, haplotype reconstruction was carried out. In
order to investigate the possible role of the HLA-DQ complex, the HLA-
DQA1 alleles were also inferred. Multivariate logistic regression analysis
and a Bayesian network-based approach were applied to identify rele-
vant genetic risk factors of asparaginase hypersensitivity. Patients with
HLA-DRB1*07:01 and HLA-DQB1*02:02 alleles had significantly higher
risk of  developing asparaginase hypersensitivity compared to non-carri-
ers [P=4.56x10-5; OR=2.86 (1.73-4.75) and P=1.85x10-4; OR=2.99 (1.68-
5.31); n=359, respectively]. After haplotype reconstruction, the HLA-
DRB1*07:01-HLA-DQB1*02:02 haplotype was associated with an
increased risk. After inferring the HLA-DQA1 alleles the 
HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplotype was
associated with the highest risk of asparaginase hypersensitivity
[P=1.22x10-5; OR=5.00 (2.43-10.29); n=257]. Significantly fewer T-cell
ALL patients carried the HLA-DQB1*02:02 allele and the associated hap-
lotype than did pre-B-cell ALL patients (6.5%; vs. 19.2%, respectively;
P=0.047). In conclusion, we identified a haplotype in the Human
Leukocyte Antigen Class II region associated with a higher risk of
asparaginase hypersensitivity. Our results confirm that variations in
HLA-D region might influence the development of asparaginase hyper-
sensitivity. 
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ABSTRACT
Introduction
Asparaginase is a pivotal component of pediatric acute lymphoblastic leukemia
(ALL) treatment. It converts asparagine to aspartic acid and ammonia.
Lymphoblast cells lose the ability to produce asparagines; hence the loss of exoge-
nous asparagine leads to cell death. However, the use of asparaginase can be chal-
lenging as either hypersensitivity reactions or neutralizing antibody formation can
occur against this heterologous enzyme. Both can consequently lead to lower
exposure to asparaginase which may result in suboptimal treatment response.1-3 In
addition, hypersensitivity reactions to asparaginase range
in severity from mild, transient (flushing or rash) to gener-
alized anaphylaxis, which can be  potentially life-threaten-
ing.4
Few studies have investigated the genetic basis of
asparaginase hypersensitivity (AH). In a genome-wide
association study (GWAS) of 485 pediatric ALL patients of
European ancestry, Chen et al. found that rs4958351 of the
glutamate receptor gene GRIA1 located at 5q33 associated
with AH.5 Recently, in a GWAS of a multiethnic cohort of
3308 patients, Fernandez et al. replicated the finding
between the rs4958351 variant and AH and found that the
association was stronger in patients treated with native
Escherichia coli-derived asparaginase (E. coli asparaginase)
than in those receiving pegylated asparaginase.6 However,
the significance of the association (P=0.03) did not reach
the genome-wide threshold (P=5 x 10-8). This association
has been replicated in a relatively small Slovenian popula-
tion of 146 patients.7 In our previous candidate-gene study,
we found that although genetic variants of GRIA1 influ-
enced the risk to AH, significant differences were
observed according to sex and patient subgroup  (T-cell or
pre-B-cell ALL).8
The association of Human Leukocyte Antigen (HLA)-
DRB1*07:01 allele with an increased risk of AH was
revealed in a candidate-gene study of Fernandez et al. of
1870 pediatric ALL patients of European ancestry.9 Later,
in the subsequent GWAS of the same group on AH, a SNP
linked to HLA-DRB1*07:01 also acted as a risk allele in
patients of diverse ancestry. In this study, the rs6021191
variant in NFATC2 was also associated with a higher risk
of AH at the genome-wide significance threshold (P=4.1 x
10-8, OR=3.11).6 The minor allele frequency (MAF) of
rs6021191 was only 0.001 among patients of European
descent; therefore, this result has more relevance in
patients of non-European ancestry.
HLA class II alleles are involved in presentation of pep-
tides derived from extracellular proteins to T cells and sub-
sequent activation of the immune response. They are
located in the Major Histocompatibility Complex region
on chromosome 6 and are expressed in antigen presenting
cells. This genetic region is highly polymorphic with con-
siderable linkage disequilibrium.
The primary goal of our study was to test the associa-
tions of HLA class II alleles with E. coli AH in a Hungarian
population of 359 pediatric ALL patients using next-gener-
ation sequencing (NGS)-based HLA typing of HLA-DRB1
and HLA-DQB1 alleles. In addition, we aimed to evaluate
the possible role of the HLA-DRB1–HLA-DQA1–HLA-
DQB1 haplotypes and the polymorphic amino acid posi-
tions located in the peptide-binding groove of the HLA-
DQ complex in the mechanism of AH. 
Methods
Patients
DNA samples from 359 pediatric ALL patients were available to
investigate the association of HLA class II alleles with AH. The
patients were treated with protocols from the Berlin-Frankfurt-
Münster Study Group (accrued patients from 1990 to 2011): ALL-
BFM 90 (n=72), ALL-BFM 95 (n=165), ALL IC-BFM 2002 (n=117),
and ALL IC-BFM 2009 (n=5). The combined chemotherapy regi-
mens contained E. coli asparaginase (Kidrolase or Asparaginase
medac) as first-line treatment. The dosing schedules of E. coli
asparaginase have been described in detail previously.8
Written informed consent was obtained from the study partici-
pants or from the next of kin, carers, or guardians on behalf of the
minors/children who took part  in the study. The study was con-
ducted according to the Declaration of Helsinki and approved by
the Hungarian Scientific and Research Ethics Committee of the
Medical Research Council (ETT TUKEB; case n.: 8-374/2009-
1018EKU 914/PI/08).
The patients had a median age of 4.8 years at diagnosis (range
1-18 years) (Table 1). The overall incidence of E. coli AH was
39.0%. Data collection was carried out retrospectively from med-
ical records. The National Cancer Institute Common Toxicity
Criteria (CTC) system v.3.0 was used to assess the grade of hyper-
sensitivity. We regarded a case as AH when signs of allergic reac-
tions or anaphylactic reactions CTC grade 1 and above were
noted, as described earlier.8
Sequence-based typing of HLA-DRB1 and DQB1
For sequencing, DNA samples from pediatric ALL patients with
peripheral blood or bone marrow origin were available.8 Only
those patients whose DNA sample met the quality control criteria
of NGS-based typing method were enrolled in this study. All of
the 359 patients were typed at high-resolution level for HLA-
DRB1 and HLA-DQB1, in the Beijing Genomics Institute (BGI)
using an NGS-based genotyping method that applies a massively
parallel paired-end sequencing on Illumina MiSeq, effective vari-
ant phasing and haploid sequence assembling pipeline, as previ-
ously described.10 Based on this, exon 2 was sequenced in 
HLA-DRB1, and exons 2 and 3 were sequenced in HLA-DQB1
genes.
Estimation of HLA-DRB1–HLA-DQA1–HLA-DQB1
haplotypes
HLA-DRB1–HLA-DQB1 haplotypes were estimated based on
HLA-DRB1 and HLA-DQB1 4-digit typing data of ALL patients by
using the PHASE software (v.2.1.1). In addition, the HLA-DRB1
and HLA-DQB1 genotypic data was used to search for three-gene
HLA-DRB1–HLA-DQA1–HLA-DQB1 haplotypes in the Allele
Frequency Net Database-HLA Haplotype Frequency Search
(http://www.allelefrequencies.net/hla6003a.asp).13 Using this
approach, it was possible to infer independently the most likely
haplotypes (including information about the HLA-DQA1 locus)
using haplotype data pertaining to Caucasoid ethnic origin as ref-
erence panel (Online Supplementary Text S1).
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Table 1. Patients’ characteristics.
Sex (%)
Male                                                                                             200 (55.7)
Female                                                                                        159 (44.3)
Age at diagnosis, years
Mean (± SD)                                                                             6.3 (±4.2)
Median (range)                                                                         4.8 (1-18)
Risk category (%)
Low-risk                                                                                      102 (28.4)
Medium-risk                                                                              213 (59.3)
High-risk                                                                                      44 (12.3)
Immunophenotype (%)
Pre-B ALL                                                                                    287 (79.9)
T-ALL                                                                                             46 (12.8)
Unknown                                                                                       26 (7.2)
SD: Standard Deviation: pre-B ALL: pre-B-cell acute lymphoblastic leukemia (ALL); T-
ALL: T-cell ALL.
Inference of polymorphic amino acid positions in HLA
class II alleles
Amino acid sequences encoded by the HLA-DRB1, HLA-DQA1
and HLA-DQB1 exon 2 were inferred using the four-digit sequenc-
ing results of HLA-DRB1 and HLA-DQB1 as well as the inference
results for HLA-DQA1. The Alignment Viewer of Database of
Major Histocompatibility Complex (dbMHC;
https://www.ncbi.nlm.nih.gov/gv/mhc/align.fcgi?cmd=aligndisplay&user
_id=0&probe_id=0&source_id=0&locus_id=0&locus_group=1&proto
_id=0&kit_id=0&banner=1) was used to assess the polymorphic
amino acid positions in HLA-DRB1, HLA-DQB1 and HLA-DQA1
chains. 
Statistical analysis
Frequentist methods: multivariate logistic regression was used to
test the associations of HLA class II alleles, HLA-DRB1–HLA-
DQA1–HLA-DQB1 haplotypes and polymorphic amino acid posi-
tions with E. coli AH. Sex, ALL immunophenotype (pre-B or T-
ALL), age at diagnosis (≤10 or >10 years), risk group (standard- or
medium- or high-risk), and treatment protocol were included in
the model as categorical covariates. Assuming an additive genetic
model, odds ratios (ORs) and 95% confidence intervals (CIs) were
obtained to estimate risks for each variable to AH. To account for
multiple testing Bonferroni correction was used (P≤2.66 x 10-4,
based on a total of 66 HLA class II alleles, 38 haplotypes and 84
polymorphic amino acid positions tested). R statistical software
(3.1.2) and IBM SPSS Statistic (v.20) software were used for analy-
ses.
BN-BMLA method: we also applied Bayesian network based
Bayesian multilevel analysis of relevance (BN-BMLA) to extend
our genetic association study by estimating a posteriori probabili-
ties of strong relevance (posteriors).14-17 The BN-BMLA method
was explained in detail in our previous studies.18-20 Briefly, it com-
putes the a posteriori probability of the strongly relevant variable
sets with respect to a target variable (e.g. a dichotomous variable
(yes/no) describing the AH status of the patients). The strongly rel-
evant variables have a direct influence on the target. Values for
posterior (P) range from 0 to 1, where P=1 and P=0 mean that the
probability of the target being dependent on a predictor (e.g. HLA
allele) is 100% and 0%, respectively. There were two types of
strong relevance: direct relevance (e.g. casual genetic variant) and
pure interaction (e.g. epistasis). For analyses, HLA-DRB1, HLA-
DQB1 and HLA-DQA1 alleles, HLA-DRB1–HLA-DQA1–HLA-
DQB1 haplotypes, sex, ALL immunophenotype, age at diagnosis,
risk group, and treatment protocol were included in the model as
predictors. 
Results
Association of HLA-DRB1 and HLA-DQB1 alleles with
asparaginase hypersensitivity
We investigated the associations of HLA class II alleles
(HLA-DRB1, HLA-DQB1 and HLA-DQA1) and haplotypes
with hypersensitivity reactions to E. coli asparaginase in
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Figure 1. Frequencies of HLA-DRB1, HLA-DQB1 and HLA-
DQA1 alleles in pediatric patients with acute lymphoblastic
leukemia. High-resolution sequence-based typing of HLA class
II alleles resulted in 35 unique HLA-DRB1 (A) and 19 unique
HLA-DRB1 (B) alleles  in 359 patients. 
HLA-DQA1 alleles were inferred in 257 patients and resulted in
7 unique alleles (C).
A B
C
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Table 2. Association of HLA-DRB1–HLA-DQB1 haplotypes with E. coli asparaginase hypersensitivity in acute lymphoblastic leukemia patients (n=359).
Haplotype Frequency OR1 95% CI2 P1
DRB1*01:01–DQB1*05:01 0.081 0.71 0.38-1.31 0.27
DRB1*01:01–DQB1*06:03 0.001 NA3 NA3 0.98
DRB1*01:02–DQB1*05:01 0.015 1.39 0.39-4.94 0.61
DRB1*03:01–DQB1*02:01 0.097 1.05 0.60-1.82 0.87
DRB1*04:01–DQB1*03:01 0.014 0.37 0.08-1.80 0.22
DRB1*04:01–DQB1*03:02 0.015 1.30 0.38-4.47 0.68
DRB1*04:01–DQB1*03:05 0.001 NA3 NA3 0.98
DRB1*04:02–DQB1*03:02 0.025 0.86 0.31-2.35 0.77
DRB1*04:03–DQB1*03:02 0.008 2.25 0.37-13.73 0.38
DRB1*04:03–DQB1*03:04 0.003 NA3 NA3 0.98
DRB1*04:03–DQB1*03:05 0.003 NA3 NA3 0.98
DRB1*04:04–DQB1*03:02 0.017 4.74 1.35-16.61 0.02
DRB1*04:04–DQB1*04:02 0.001 NA3 NA3 0.98
DRB1*04:05–DQB1*03:02 0.004 NA3 NA3 0.99
DRB1*04:07–DQB1*03:01 0.004 1.35 0.12-15.78 0.81
DRB1*04:08–DQB1*03:04 0.007 2.47 0.39-15.55 0.34
DRB1*04:10–DQB1*04:02 0.001 NA3 NA3 0.98
DRB1*07:01–DQB1*02:02 0.091 2.99 1.68-5.31 1.85 x 10-4
DRB1*07:01–DQB1*03:03 0.038 1.71 0.76-3.84 0.20
DRB1*08:01–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*08:01–DQB1*03:02 0.001 NA3 NA3 0.98
DRB1*08:01–DQB1*04:02 0.036 0.48 0.18-1.26 0.13
DRB1*08:04–DQB1*04:02 0.001 NA3 NA3 0.98
DRB1*09:01–DQB1*03:03 0.008 1.63 0.31-8.64 0.57
DRB1*10:01–DQB1*05:01 0.017 0.12 0.02-0.98 0.05
DRB1*11:01–DQB1*03:01 0.070 0.40 0.19-0.82 0.01
DRB1*11:03–DQB1*03:01 0.010 1.13 0.24-5.32 0.88
DRB1*11:04–DQB1*03:01 0.060 1.30 0.67-2.54 0.44
DRB1*11:15–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*11:43–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*12:01–DQB1*03:01 0.013 2.34 0.60-9.12 0.22
DRB1*12:01–DQB1*03:12 0.003 NA3 NA3 0.98
DRB1*12:02–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*13:01–DQB1*06:02 0.001 NA3 NA3 0.98
DRB1*13:01–DQB1*06:03 0.071 0.51 0.26-1.00 0.05
DRB1*13:02–DQB1*06:03 0.001 NA3 NA3 0.98
DRB1*13:02–DQB1*06:04 0.019 0.90 0.28-2.90 0.85
DRB1*13:02–DQB1*06:09 0.004 0.81 0.07-9.13 0.86
DRB1*13:03–DQB1*03:01 0.019 0.61 0.18-2.06 0.43
DRB1*13:05–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*13:15–DQB1*03:01 0.001 NA3 NA3 0.98
DRB1*13:18–DQB1*06:03 0.001 NA3 NA3 0.98
DRB1*14:04–DQB1*05:03 0.017 1.23 0.38-4.01 0.73
DRB1*14:54–DQB1*05:02 0.004 1.23 0.37-48.73 0.25
DRB1*14:54–DQB1*05:03 0.028 0.72 0.26-1.97 0.52
DRB1*15:01–DQB1*05:02 0.006 0.49 0.05-5.17 0.55
DRB1*15:01–DQB1*06:01 0.001 NA3 NA3 0.98
DRB1*15:01–DQB1*06:02 0.070 1.32 0.70-2.47 0.39
DRB1*15:01–DQB1*06:03 0.001 NA3 NA3 0.98
DRB1*15:01–DQB1*06:39 0.001 NA3 NA3 0.98
DRB1*15:02–DQB1*05:03 0.008 NA3 NA3 0.98
DRB1*15:02–DQB1*06:01 0.017 0.22 0.05-1.06 0.06
DRB1*16:01–DQB1*05:02 0.064 1.25 0.66-2.38 0.50
DRB1*16:01–DQB1*05:05 0.001 NA3 NA3 0.98
DRB1*16:01–DQB1*06:02 0.001 NA3 NA3 0.98
DRB1*16:02–DQB1*05:02 0.007 0.45 0.05-4.10 0.48
Results that reached the significance threshold (P≤2.66 x 10-4) are in bold. NA: not available. 1For the association between the allele and asparaginase hypersensitivity. 295% con-
fidence interval for the estimated odds ratio. 3The odds ratios and confidence intervals were not estimated due to low allele frequency..
pediatric ALL patients. Among 359 patients, the high-res-
olution sequence-based typing resulted in 35 unique HLA-
DRB1 and 19 unique HLA-DQB1 alleles (Figure 1A and B). 
Univariate and multivariate logistic regression was per-
formed to test the potential risk factors for AH (Online
Supplementary Table S1). The incidence of AH varied by
risk group (P=5.7 x 10-5), ranging from 31% for 
medium-risk group to 77% for the high-risk group and
treatment protocol (P=3.36 x 10-3), ranging from 26% for
ALL-BFM 90 to 60% for ALL IC-BFM 2002 experimental
protocol (Online Supplementary Table S1). Using multivari-
ate analysis risk group and treatment protocol also
showed significant association with AH (Online
Supplementary Table S1). For analyses with genetic data,
we included all risk factors in the model as categorical
covariates.
Applying Bonferroni correction (P≤2.66x10-4) in multi-
variate logistic regression analyses HLA-DRB1*07:01 and
HLA-DQB1*02:02 alleles showed significant associations
with E. coli AH in 359 pediatric ALL patients (Figure 2).
None of the patients was homozygous for either allele.
Patients with HLA-DRB1*07:01 allele had significantly
higher risk of developing AH compared to non-carriers
[P=4.56x10-5; OR=2.86 (1.73-4.75)] (Figure 3). Similarly,
patients harboring HLA-DQB1*02:02 were at greater risk
of having AH [P=1.85x10-4; OR=2.99 (1.68-5.31)] (Figure
3). Allelic odds ratios and the AH rate of patients depend-
ing on the carrier state are shown in Online Supplementary
Table S2.
There was a significant difference in the proportion of
HLA-DQB1*02:02 carriers between patients with pre-B-
cell and T-cell ALL (19.2% vs. 6.5%; in patients with pre-
B-cell and T-cell ALL, respectively; P=0.047). No such dif-
ference could be detected in the case of HLA-DRB1*07:01
carriers.
The BN-BMLA approach was used to investigate the
different dependency relations between HLA alleles, age,
ALL immunophenotype, sex, treatment protocol, risk
group, and AH. The analysis revealed that if both HLA-
DRB1 and HLA-DQB1 alleles were included in the
Bayesian Network, among genetic factors only HLA-
DQB1*02:02 allele had direct strong relevance to AH
(P=0.95) beside the influence of the risk group status
(P=1.00) (Figure 4). There was no interaction or redundan-
cy between predictors.
Haplotype estimation and the inference of HLA-DQA1
alleles
In order to further investigate the relationship between
HLA-DRB1*07:01 and HLA-DQB1*02:02 alleles associated
with AH, we estimated haplotypes using the PHASE soft-
ware (v.2.1.1). Using this method, the haplotype recon-
struction resulted in 56 different haplotypes (Table 2).
Two haplotypes containing HLA-DRB1*07:01 allele were
estimated among patients: HLA-DRB1*07:01–HLA-
DQB1*02:02 and HLA-DRB1*07:01–HLA-DQB1*03:03.
Out of these, only HLA-DRB1*07:01–HLA-DQB1*02:02
showed a positive association with AH [P=1.85 x 10-4;
OR=2.99 (1.68-5.31)] (Table 2). According to this, the
HLA-DRB1*07:01 and HLA-DQB1*02:02 are risk alleles
and in contrast to the HLA-DRB1*07:01–HLA-
DQB1*03:03 haplotype, HLA-DRB1*07:01–HLA-
DQB1*02:02 reached statistical significance. This is in
agreement  with the result of the BN-BMLA, i.e. in respect
of AH, the presence of HLA-DQB1*02:02 seems to be
important.
Next, the HLA-DRB1-HLA-DQA1-HLA-DQB1 haplo-
types were independently inferred by using reference data
from The Allele Frequency Net Database. The aim of
inferring HLA-DQA1 alleles was to investigate the possi-
ble role of the structure of the HLA-DQ complex in the
pathomechanism of AH. In contrast to the HLA-DR com-
plex, the alpha chain is also polymorphic in the HLA-DQ
heterodimer, therefore polymorphic amino acid positions
in HLA-DQA1 may also influence the peptide preference
of the HLA-DQ complexes and consequently the develop-
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Figure 2. Association of HLA-DQB1 and HLA-DQB1 alleles with E. coli asparaginase hypersensitivity. Multivariate logistic regression was applied to assess the asso-
ciation of HLA class II alleles with asparaginase hypersensitivity. Sex, age, treatment protocol, risk group, acute lymphoblastic leukemia (ALL) immunophenotype were
included in the analysis as categorical covariates. The dashed horizontal line indicates the Bonferroni-corrected statistical significance threshold. HLA-DRB1*07:01
and HLA-DQB1*02:02 alleles were significantly associated with asparaginase hypersensitivity (n=359; P=4.56x10-5 and 1.85x10-4, respectively).
ment of a specific immune response against asparaginase.
Using data for haplotype frequencies in Caucasoid popu-
lations, and applying the aforementioned method, the
estimation of extended haplotypes was possible in 72% of
the patients (n=257; Online Supplementary Table S3). We
compared the haplotype estimation results obtained by
using the PHASE software to those extended haplotype
data inferred by using The Allele Frequency Net Database.
Results were in 100% agreement. Finally, among these
257 patients, 7 unique HLA-DQA1 alleles were inferred
(Figure 1C). 
Multivariate logistic regression analysis showed that
HLA-DQA1*02:01 allele and HLA-DRB1*07:01–HLA-
DQA1*02:01–HLA-DQB1*02:02 haplotype were positive-
ly and significantly associated with AH [P=3.45x10-5;
OR=3.69 (1.99-6.84) and P=1.22x10-5; OR=5.00 (2.43-
10.29), respectively] (Online Supplementary Table S3).
These statistical associations were equivalent to the asso-
ciations of HLA-DRB1*07:01 and HLA-DQB1*02:02 alle-
les, respectively; hence HLA-DQA1*02:01 exclusively and
in all cases occurred together with HLA-DRB1*07:01.
Inference of polymorphic amino acid positions in HLA
class II alleles
A total of 84 polymorphic amino acid positions were
identified from 4-digit typing results of HLA-DRB1 and
HLA-DQB1 genes and from inferred HLA-DQA1 allelic
data using dbMHC database. In order to further investi-
gate the possible sequence features that confer a greater
risk to AH, multivariate logistic regression was performed
to test for associations between polymorphic amino acid
positions in HLA class II alleles and AH. In our patients
with leukemia, a total of 27 positions associated signifi-
cantly (Table 3).
A valine at position 78 in HLA-DRB1 showed the
strongest association with AH [P=8.16x10-6; OR=4.01
(2.18-7.37)] (Table 3). Out of the 27 risk amino acids, 7 and
3 were uniquely coded by HLA-DRB1*07:01 and HLA-
DQA1*02:01, respectively [P=3.45x10-5; OR=3.69 (1.99-
6.84)] (Table 3). All positions with risk amino acids in
HLA-DQB1 belonged to at least two alleles and were, to a
lesser extent, associated with hypersensitivity 
[P=1.69x10-4; OR=2.87 (1.66-4.97)] (Table 3). 
Interestingly, while all amino acids conferring risk to AH
were present in HLA-DQB1*02:02; the other HLA-DQB1
allele linked to HLA-DRB1*07:01, HLA-DQB1*03:03 pos-
sessed no risk amino acid at any risk position. These
results confirm the important role of the HLA-
DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplo-
type in the increased risk of AH. 
Discussion
The aim of our study was to investigate the association
of the variations in the HLA class II region with E. coli AH
in pediatric ALL patients. By analyzing 359 Hungarian
patients, we found that HLA-DRB1*07:01 and HLA-
DQB1*02:02 were associated with an increased risk of
developing AH. Haplotype reconstruction also revealed
that the HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-
DQB1*02:02 haplotype positively and significantly associ-
ated with an increased risk of AH.
Previously, in 2014,  a study by Fernandez et al. of 1870
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Figure 3. Patients carrying the HLA-
DRB1*07:01 or HLA-DQB1*02:02
alleles had strong association with
asparaginase hypersensitivity. The
incidence of hypersensitivity reac-
tions was 57% (52 of 92) and 33%
(88 of 267) for patients carrying 
HLA-DRB1*07:01 allele and for non-
carriers, respectively. In the case of
patients with HLA-DQB1*02:02
allele, the incidence of asparagi-
nase hypersensitivity was 60% (39
of 65), while it was 34% (101 of
294) for patients who did not have
the allele. Odds ratios (OR) and 95%
confidence intervals were estimated
by using multivariate logistic regres-
sion analysis.
pediatric ALL patients of European ancestry revealed the
association of HLA-DRB1*07:01 allele with AH.9 Later, the
same group confirmed the role of this allele in an ethnical-
ly diverse pediatric population. In our study, we also con-
firmed these findings, but after haplotype reconstruction
we also found that only the HLA-DRB1*07:01–HLA-
DQB1*02:02 haplotype associated significantly, and  the
HLA-DRB1*07:01–HLA-DQB1*03:03 haplotype did not
reach statistical significance, possibly because of the lower
allele frequency (0.038 vs. 0.091 for the HLA-DRB1*07:01–
HLA-DQB1*02:02 haplotype). However, further investiga-
tions are warranted to elucidate the actual causality. The
importance of the HLA-DQB1*02:02 allele in the hyper-
sensitivity was also shown by the BN-BMLA method,
which showed that if both HLA-DRB1 and HLA-DQB1
alleles were included in the Bayesian Network only HLA-
DQB1*02:02 allele had direct strong relevance to AH with
a high posterior probability (0.95). The situation is the
same with the HLA-DQA1*02:01 allele as with the HLA-
DRB1*07:01 allele, because they are in complete linkage
disequilibrium with each other. This may suggest that, in
our population, the HLA-DQB1*02:02 allele also seems to
be an important genetic risk factor for AH in this region.
However, when the amino acid results are evaluated,
there is some controversy in this statement. It is well
known that proteins coded by the HLA-D, or also known
as the MHC class II genes play a critical role in the
immune response to extracellular antigens. Antigen pre-
senting cells present processed antigens, or epitopes
bound in a pocket formed by the MHC II chains to T-cell
receptors on the surface of helper T cells, resulting in
cytokine secretion by T cells leading to, among others, dif-
ferentiation of B cells into antibody-secreting plasma cells.
According to the theory, the stronger the MHC II protein
binds an epitope, the stronger the immune response is.
The strength of the binding is determined by the 3D struc-
ture of the MHC II protein which depends on its amino
acid composition. Table 2 shows the amino acids associat-
ed with the AH and the different HLA class II alleles cod-
ing for these variants. Regarding E. coli asparaginase epi-
topes, Fernandez et al. predicted with bioinformatic meth-
ods that the HLA-DRB1*07:01 is a high binding allele
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Table 3. Polymorphic amino acid positions in HLA-DRB1, HLA-DQB1 and HLA-DQA1 associated with E. coli asparaginase hypersensitivity in acute
lymphoblastic leukemia  patients (n=257).
HLA class II AA Risk OR3 95% P3 Other possible HLA class II alleles with risk residue
locus position1 residue2 CI4 amino acids5
HLA-DRB1 10 Q 2.22 1.45-3.40 2.30×10-4 E,Y *01:01, *01:02, *04:01, *04:02, *04:03, *04:04, *04:05, *04:07,
*07:01, *09:01, *15:01, *15:02,*16:01, *16:02 
11 G 3.69 1.99-6.84 3.45×10-5 D,L,P,S,V *07:01
13 Y 3.69 1.99-6.84 3.45×10-5 F,G,H,R,S *07:01
14 K 3.69 1.99-6.84 3.45×10-5 E *07:01
25 Q 3.69 1.99-6.84 3.45×10-5 R *07:01
30 L 3.69 1.99-6.84 3.45×10-5 C,G,H,R,Y *07:01
37 F 3.69 1.99-6.84 3.45×10-5 L,N,S,Y *07:01
57 V 3.52 2.00-6.19 1.31×10-5 D,S *07:01, *09:01, *12:01
60 S 3.52 2.00-6.19 1.31×10-5 Y *07:01, *09:01, *12:01
73 G 2.96 1.71-5.12 1.10×10-4 A *07:01, *03:01
74 Q 3.69 1.99-6.84 3.45×10-5 A,E,L,R *07:01
78 V 4.01 2.18-7.37 8.16×10-6 Y *07:01, *09:01
HLA-DQA1 47 K 3.69 1.99-6.84 3.45×10-5 C,Q,R *02:01
50 L 3.03 1.78-5.14 4.09×10-5 E,V *02:01, *03:01
52 H 3.69 1.99-6.84 3.45×10-5 R,S *02:01
53 R 3.03 1.78-5.14 4.09×10-5 K,Q *02:01, *03:01
54 L 3.69 1.99-6.84 3.45×10-5 F *02:01
HLA-DQB1 28 S 2.87 1.66-4.97 1.69×10-4 T *02:01, *02:02
30 S 2.87 1.66-4.97 1.69×10-4 H,Y *02:01, *02:02
37 I 2.87 1.66-4.97 1.69×10-4 D,Y *02:01, *02:02
46 E 2.87 1.66-4.97 1.69×10-4 V *02:01, *02:02
47 F 2.87 1.66-4.97 1.69×10-4 Y *02:01, *02:02
52 L 2.87 1.66-4.97 1.69×10-4 P *02:01, *02:02
55 L 2.87 1.66-4.97 1.69×10-4 P,R *02:01, *02:02
57 A 2.60 1.58-4.26 1.61×10-4 D,S,V *02:01, *02:02, *03:02, *03:04, *03:05
71 K 2.87 1.66-4.97 1.69×10-4 A,D,T *02:01, *02:02
74 A 2.87 1.66-4.97 1.69×10-4 E,S *02:01, *02:02
HLA class II alleles significantly associated with asparaginase hypersensitivity are in bold. 1Amino acid (AA) position of the HLA class II protein sequence without the leader
signal sequence.  2Amino acid associated with asparaginase hypersensitivity.  3For the association between the allele and asparaginase hypersensitivity.  495% confidence interval
for the estimated odds ratio.  5Other possible amino acids refer to other amino acids within that amino acid position observed in our patients (n=257).
which could be the reason for  its association with AH. In
our results, several amino acids within the HLA-DQB1
protein were also associated with increased AH, and all of
them were present in HLA-DQB1*02:02. But they were
also present in HLA-DQB1*02:01 which was not associat-
ed with AH. It means that from these amino acid results it
cannot be predicted why amino acids in HLA-
DQB1*02:02 were associated with AH. This may mean
that although the presence of HLA-DQB1*02:02 allele may
be decisive in the development of AH, the presence of the
HLA-DRB1*07:01 and/or HLA-DQA1*02:01 alleles may
also be necessary for the increased risk, raising the possi-
bility that it is the extended haplotype rather than the
individual alleles that  is important in this respect.
There was another interesting finding in the present
study. A significantly smaller proportion of T-cell ALL
patients carried the HLA-DQB1*02:02 allele than did pre-
B-cell ALL patients (6.5%; vs. 19.2% of patients with T-
cell and pre-B-cell ALL, respectively). This may suggest
two interpretations. Either the allele increases the risk to
pre-B-cell ALL or decreases the risk to T-cell ALL. Earlier
the HLA-DQB1*02:02 allele was found to be associated
with increased risk of celiac disease indicating its autoim-
munogenic potential.21 Although we did not determine its
allele frequency in a healthy control population, its fre-
quency data in The Allele Frequency Net Database in
Caucasian populations were around the value found in the
pre-B-cell ALL patients in our study. Thus, in contrast its
role in celiac disease, the HLA-DQB1*02:02 allele might
decrease the risk of the development of T-cell ALL.
Furthermore, because this allele is always on the HLA-
DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplo-
type, this could mean that this haplotype might provide
some protection against development of T-cell ALL but
not against pre-B-cell ALL. Naturally, subjects from the
same population must be compared to test this assump-
tion.
This study has some limitations. First, patients who
died during the chemotherapy due to therapy-resistant
progressive disease, or due to infections or toxicities of
therapy are under-represented in our ALL population.
Furthermore, data about hypersensitivity reactions to 
E. coli asparaginase was collected retrospectively from the
patients' files. This  does not allow for meticulous docu-
mentation or  fine grading of hypersensitivity reactions.
In some cases the inference of HLA-DQA1 alleles could
not be precisely carried out. For further analyses with
HLA-DQA1 alleles, data from undetermined haplotypes
were merged into one of the possible HLA-DQA1 allele
categories (Online Supplementary Table S4). In most cases,
exon 2 of the involved alleles was identical at the amino
acid sequence level and no haplotype was found with the
other HLA-DQA1 allele in The Allele Frequency Net
Database either. In the case of HLA-DRB1*13:01–HLA-
DQA1*01:02/*01:03–HLA-DQB1*06:03 haplotype, the
HLA-DQA1 allele was regarded as HLA-DQA1*01:03
because it was more likely based on the overall Caucasian
haplotype frequency data. To increase the reliability of our
inference results, a strict algorithm was applied, which led
to the over-representation of common haplotypes.
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Figure 4. A posteriori strong relevance of predictors to asparaginase hypersensitivity. The BN-BMLA approach was used to investigate the different dependency rela-
tions between HLA alleles, age, acute lymphoblastic leukemia (ALL) immunophenotype, sex, treatment protocol, risk group and asparaginase hypersensitivity. 
HLA-DQB1*02:02 allele and risk group had direct strong relevance to asparaginase hypersensitivity (P=0.95 and 1.00, respectively).
There are, however, several strengths to this study. First,
we studied a relatively large and homogenous European
population (Hungarian). Second, we used NGS technolo-
gy to determine the HLA-DQB1 and HLA-DQB1 HLA
types, which is more accurate than the SNP-based impu-
tation used in other studies. In addition, the nucleotide
sequence-based HLA typing, in contrast to the costly and
laborious direct experimental HLA typing, allows  poly-
morphic HLA amino acid positions from the HLA alleles
to be inferred. Third, ours is the first study to evaluate the
role of HLA haplotypes in AH, and our results indicated
that the HLA haplotype-based risk prediction might be
more precise than the single allele-based risk calculation.
In conclusion, in our study, we found that the 
HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02
haplotype was associated with a high risk of E. coli AH in
pediatric ALL patients. Based on our results, besides the
previously described HLA-DRB1*07:01 allele, the 
HLA-DQB1*02:02 allele might also be important in the
development of AH. This  needs further investigation. 
N. Kutszegi et al.
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